tiprankstipranks
Trending News
More News >
Serina Therapeutics (SER)
:SER
Advertisement

Serina Therapeutics (SER) AI Stock Analysis

Compare
197 Followers

Top Page

SE

Serina Therapeutics

(NYSE MKT:SER)

Rating:47Neutral
Price Target:
$5.00
▼(-6.72%Downside)
The overall stock score for Serina Therapeutics reflects significant financial challenges, including substantial losses and negative cash flow, which are the most impactful factors. The bearish technical indicators and negative valuation metrics further weigh on the stock's prospects. However, the recent breakthrough in LNP technology provides a positive aspect, potentially improving the company's future strategic position.
Positive Factors
Drug Innovation
SER-252 could represent a best-in-class solution for deployment of apomorphine in advanced PD patients.
Market Potential
POZ-Apomorphine targets substantial Advanced Parkinson's Disease market with potential for key clinical/commercial advantages.
Regulatory Approval
The discussion highlighted the company's clear vision of SER-252's path for regulatory approval, with a potential for 505(b)2 and associated reductions in timelines and costs, and their confidence they can reach the clinical benchmarks required to be approved.
Negative Factors
Current Treatment Challenges
Current formulations of apomorphine (APOKIN and ONAPGO, both marketed by Supernus Pharmaceuticals) have severe adverse events, which can hinder treatment compliance.
Market Competition
63% of patients treated with competing product ONAPGO experience infusion site reactions, highlighting potential challenges in the market.

Serina Therapeutics (SER) vs. SPDR S&P 500 ETF (SPY)

Serina Therapeutics Business Overview & Revenue Model

Company DescriptionSerina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
How the Company Makes MoneySerina Therapeutics makes money by developing and licensing its proprietary POZ technology to pharmaceutical companies seeking to improve the delivery and efficacy of their existing drugs. The company generates revenue through licensing agreements, research and development collaborations, and royalty payments from its partners. These partnerships enable Serina Therapeutics to leverage its technology in combination with the drug development expertise of its partners, thereby expanding its reach and market potential. Additionally, the company may receive milestone payments based on the successful development and commercialization of products utilizing its technology, contributing to its overall revenue streams.

Serina Therapeutics Financial Statement Overview

Summary
Serina Therapeutics is facing severe financial challenges across all key financial statements. The income statement reflects substantial losses and declining revenue, the balance sheet is under strain due to high liabilities and negative equity, and cash flow issues point to operational inefficiencies. These factors collectively suggest a need for strategic restructuring or significant operational improvements to ensure future viability.
Income Statement
20
Very Negative
Serina Therapeutics has experienced significant volatility in revenue and profitability. The TTM data shows a drastic decline in revenue, leading to negative gross and net profit margins. This indicates severe inefficiencies and a struggle to generate sufficient income. Previous periods also reflect a trend of high losses, with EBIT and EBITDA margins persistently underperforming.
Balance Sheet
30
Negative
The balance sheet shows a concerning financial structure with a very low equity base and high liabilities, resulting in a negative equity in some periods. The debt-to-equity ratio is not ideal, and the return on equity is not calculable due to negative equity. This suggests high financial risk and instability.
Cash Flow
25
Negative
The cash flow statement highlights consistent negative free cash flow, indicating operational challenges. The operating cash flow is significantly negative, suggesting that the company struggles to generate cash from its core activities. Despite some positive financing activities, the overall cash flow position is weak.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue56.00K3.15M500.00K3.04M54.00K
Gross Profit-138.00K-29.00K355.00K2.89M-1.23M
EBITDA-10.49M5.92M-2.60M-7.35M-8.74M
Net Income-11.14M5.27M-2.68M-8.68M-10.87M
Balance Sheet
Total Assets6.72M11.96M858.04K1.84M3.92M
Cash, Cash Equivalents and Short-Term Investments3.67M345.00K532.23K1.31M527.00K
Total Debt268.00K4.37M1.81M398.17K6.30M
Total Liabilities6.22M6.61M38.64M36.95M9.32M
Stockholders Equity641.00K5.47M-37.78M-35.11M-5.12M
Cash Flow
Free Cash Flow-17.16M-2.98M-2.09M-2.36M-7.84M
Operating Cash Flow-17.14M-2.48M-2.08M-2.25M-7.82M
Investing Cash Flow-22.00K-504.00K980.94K823.32K-20.00K
Financing Cash Flow13.21M10.07M1.31M1.08M5.96M

Serina Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price5.36
Price Trends
50DMA
5.76
Negative
100DMA
5.42
Negative
200DMA
5.46
Negative
Market Momentum
MACD
-0.14
Positive
RSI
44.32
Neutral
STOCH
28.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SER, the sentiment is Negative. The current price of 5.36 is below the 20-day moving average (MA) of 5.69, below the 50-day MA of 5.76, and below the 200-day MA of 5.46, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 44.32 is Neutral, neither overbought nor oversold. The STOCH value of 28.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SER.

Serina Therapeutics Risk Analysis

Serina Therapeutics disclosed 78 risk factors in its most recent earnings report. Serina Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Serina Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
¥347.74B11.06-2.99%3.68%11.77%-10.16%
54
Neutral
$75.50M-1546.58%-19.45%31.22%
51
Neutral
$53.65M-59.49%21.15%46.44%
50
Neutral
$52.57M-119.22%25.51%
SESER
47
Neutral
$53.43M45.59%34.04%55.34%
46
Neutral
$54.80M-290.21%-100.00%44.28%
39
Underperform
$64.19M-679.15%-56.88%-57.57%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SER
Serina Therapeutics
5.36
-3.98
-42.61%
PDSB
PDS Biotechnology
1.15
-2.75
-70.51%
VRCA
Verrica Pharmaceuticals
0.82
-6.24
-88.39%
STRO
Sutro Biopharma
0.76
-3.23
-80.95%
KRON
Kronos Bio
0.88
-0.37
-29.60%
GANX
Gain Therapeutics
1.58
0.42
36.21%

Serina Therapeutics Corporate Events

Shareholder Meetings
Serina Therapeutics Announces 2025 Annual Meeting Date
Neutral
Jul 1, 2025

Serina Therapeutics announced that its 2025 annual meeting of stockholders will be held on November 7, 2025. The change in the meeting date from the previous year affects the deadline for stockholder proposals, which is set for August 15, 2025. This adjustment provides stakeholders with a new timeline for submitting proposals and nominations, ensuring compliance with regulatory requirements and the company’s bylaws.

The most recent analyst rating on (SER) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.

Executive/Board Changes
Serina Therapeutics Appoints Dr. Stephen Brannan to Board
Neutral
May 22, 2025

On May 22, 2025, Serina Therapeutics announced the appointment of Dr. Stephen Brannan to its Board of Directors, bringing extensive expertise in neuroscience and neuropsychiatry drug development. Dr. Brannan’s experience, notably his role in the successful development of KarXT at Karuna Therapeutics, aligns with Serina’s focus on long-acting CNS treatments. Concurrently, Remy Gross departed from the Board, transitioning to a consulting role, having contributed significantly to Serina’s growth.

The most recent analyst rating on (SER) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 15, 2025